Related references
Note: Only part of the references are listed.Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Flubendazole, FDA-approved anthelmintic, elicits valid antitumor effects by targeting P53 and promoting ferroptosis in castration-resistant prostate cancer
Xumin Zhou et al.
PHARMACOLOGICAL RESEARCH (2021)
SHP2-Mediated Inhibition of DNA Repair Contributes to cGAS-STING Activation and Chemotherapeutic Sensitivity in Colon Cancer
Bin Wei et al.
CANCER RESEARCH (2021)
Cyclodextrin-Based Hybrid Polymeric Complex to Overcome Dual Drug Resistance Mechanisms for Cancer Therapy
Lingjie Ke et al.
POLYMERS (2021)
Carbon Monoxide Inhibits Cytochrome P450 Enzymes CYP3A4/2C8 in Human Breast Cancer Cells, Increasing Sensitivity to Paclitaxel
Brian Kawahara et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Characterization of Novel Progression Factors in Castration-Resistant Prostate Cancer Based on Global Comparative Proteome Analysis
Ann-Yae Na et al.
CANCERS (2021)
Lovastatin Inhibits EMT and Metastasis of Triple-Negative Breast Cancer Stem Cells Through Dysregulation of Cytoskeleton-Associated Proteins
Chanjuan Zheng et al.
FRONTIERS IN ONCOLOGY (2021)
PSMA-11-PET/CT versus choline-PET/CT to guide stereotactic ablative radiotherapy for androgen deprivation therapy deferral in patients with oligometastatic prostate cancer
Charlotte L. Deijen et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2021)
Mechanism of Anti-Cancer Activity of Curcumin on Androgen-Dependent and Androgen-Independent Prostate Cancer
Nurul Azwa Abd Wahab et al.
NUTRIENTS (2020)
HMGB1 release promotes paclitaxel resistance in castration-resistant prostate cancer cells via activating c-Myc expression
Xiu Lei et al.
CELLULAR SIGNALLING (2020)
Can CYP Inhibition Overcome Chemotherapy Resistance?
Magnus Ingelman-Sundberg et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2020)
Cytochrome P450 3A4, 3A5, and 2C8 expression in breast, prostate, lung, endometrial, and ovarian tumors: relevance for resistance to taxanes
Maarten van Eijk et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics?
Rui-Mei Feng et al.
CANCER COMMUNICATIONS (2019)
Synergistically Enhanced Inhibitory Effects of Pullulan Nanoparticle-Mediated Co-Delivery of Lovastatin and Doxorubicin to Triple-Negative Breast Cancer Cells
Di Wu et al.
NANOSCALE RESEARCH LETTERS (2019)
Nitro aspirin (NCX4040) induces apoptosis in PC3 metastatic prostate cancer cells via hydrogen peroxide (H2O2)-mediated oxidative stress
Somaiah Chinnapaka et al.
FREE RADICAL BIOLOGY AND MEDICINE (2019)
Cerasomal Lovastatin Nanohybrids for Efficient Inhibition of Triple-Negative Breast Cancer Stem Cells To Improve Therapeutic Efficacy
Liujiang Song et al.
ACS APPLIED MATERIALS & INTERFACES (2018)
Inhibition of cancer antioxidant defense by natural compounds
Alicja Sznarkowska et al.
ONCOTARGET (2017)
Functional analysis implicating the SNP rs61552325 in ERBB2 as an effector for androgen-insensitive prostate cancer cell invasion
Xianxiang Xin et al.
ONCOTARGET (2017)
Lovastatin Inhibits Cancer Stem Cells and Sensitizes to Chemo- and Photodynamic Therapy in Nasopharyngeal Carcinoma
Yikun Peng et al.
JOURNAL OF CANCER (2017)
Statin derivatives as therapeutic agents for castration-resistant prostate cancer
Matthew A. Ingersoll et al.
CANCER LETTERS (2016)
Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds
Roberto Wuerth et al.
DRUG DISCOVERY TODAY (2016)
High-risk prostate cancer-classification and therapy
Albert J. Chang et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Beneficial effects of Monascus purpureus NTU 568-fermented products: a review
Yeu-Ching Shi et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2011)
Lovastatin Sensitizes Lung Cancer Cells to Ionizing Radiation Modulation of Molecular Pathways of Radioresistance and Tumor Suppression
Toran Sanli et al.
JOURNAL OF THORACIC ONCOLOGY (2011)
Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance
Anna Martirosyan et al.
BMC CANCER (2010)
MiR-148a Attenuates Paclitaxel Resistance of Hormone-refractory, Drug-resistant Prostate Cancer PC3 Cells by Regulating MSK1 Expression.
Yasunori Fujita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
The establishment of two paclitaxel-resistant prostate cancer cell lines and the mechanisms of paclitaxel resistance with two cell lines
Masashi Takeda et al.
PROSTATE (2007)
Cytochrome P450 pharmacogenetics and cancer
C Rodriguez-Antona et al.
ONCOGENE (2006)
Effects of statins and farnesyltransferase inhibitors on the development and progression of cancer
MR Graaf et al.
CANCER TREATMENT REVIEWS (2004)
Expression of paclitaxel-inactivating CYP3A activity in human colorectal cancer:: implications for drug therapy
C Martínez et al.
BRITISH JOURNAL OF CANCER (2002)
Induction of cytochrome P450 3A4 by docetaxel in peripheral mononuclear cells and its expression in lung cancer
K Fujitaka et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2001)